AngioDynamics Inc. has announced its plan to launch a new varicose vein therapy brand, VenaCure EVLT. The new brand will encompass the best of AngioDynamics’ VenaCure(R) product line as well as EVLT(R), a product line which AngioDynamics recently rescued from the bankruptcy of Diomed Inc. The product is an outpatient alternative to otherwise painful and invasive surgery for patients. VenaCure EVLT provides physicians continuous support from AngioDynamics to develop their clinical practices and provide patients with the best treatment available.

The U.S. Food and Drug Administration has approved CV Therapeutics’ Ranexa (ranolazine) for treating chronic angina. The changed labeling also informs that Ranexa showed better results for conditions like arrhythmias, new onset atrial fibrillation and bradycardia (dangerously slow heartbeat in patients of coronary artery disease). Also, the labeling mentions that Ranexa lowers hemoglobin A1c (HbA1c) in diabetes patients. The drug can now be used as a part of optimal therapy. Neither it reduces heart rate nor blood pressure. Unlike other long acting nitrates, Ranexa is prescribed for patients taking oral treatments for erectile dysfunction.